Építés alatt – nem éles oldal
Belépés
Résztvevőt keres2. fázis

Vericiguat for the Inhibition of Calcific Aortic Valve Stenosis Progression

A legfontosabb adatok

Ki végzi
West China Hospital
Hol
Kína1 helyszín, 1 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Toboroz
Fázis
2. fázis
Résztvevők
238 fő, tervezett
Kezdés
2026. szept. 24.
Várható befejezés
2029. nov. 30.
A vizsgálat típusa
Beavatkozással járó, 2 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
A vizsgált kezelések
  • Vericiguat (BAY1021189)
  • Placebo
A regiszteradat frissítve
2026. szeptember 25.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

The trial is looking for adults with mild-to-moderate calcific aortic valve stenosis, a narrowing of a heart valve caused by calcium build-up. It tests whether vericiguat slows the disease compared with placebo.

Életkor
35 to under 80 years.
Nem
Men and women can join. Women who can become pregnant must agree to avoid pregnancy until 4 weeks after the trial ends.
A betegség stádiuma
Mild-to-moderate aortic valve stenosis not caused by rheumatic disease, confirmed by heart ultrasound: peak aortic jet velocity ≥ 2.5 m/s and < 4.0 m/s, aortic valve area > 1.0 cm², and mean pressure gradient < 40 mmHg.
Korábbi kezelés
People who used medicines acting on the NO-sGC-cGMP pathway (such as sildenafil or nitrates) within 1 month before screening cannot join. People currently taking warfarin cannot join.
Biomarker vagy leletérték
Aortic valve calcium score (Agatston score) of at least 200 AU on heart CT.

A részvétel fő kizáró okai

  • Severe or very mild aortic stenosis, or a planned valve repair or replacement.
  • Moderate or worse leaking of other heart valves, or rheumatic valve disease.
  • Heart pumping strength (LVEF) below 50%, or NYHA class III-IV heart failure.
  • Systolic blood pressure below 120 mmHg or a history of symptomatic low blood pressure.
  • Kidney filtration rate below 15 mL/min/1.73 m², or on dialysis.

A regiszter feltételei, szó szerint

Mind a 27 feltétel megnézéseKevesebb

Ki vehet részt

  • The participant agrees to enter this clinical trial and consents to long-term follow-up
  • 35 ≤ age < 80 years
  • Echocardiographically confirmed mild-to-moderate (peak aortic jet velocity ≥ 2.5 m/s and < 4.0 m/s, aortic valve area > 1.0 cm², and mean aortic valve pressure gradient < 40 mmHg) non-rheumatic aortic valve stenosis
  • Baseline aortic valve calcium score (Agatston score) ≥ 200 AU as measured by cardiac CT
  • Male participants, or female participants who are not of childbearing potential, or female participants who commit to avoiding pregnancy through 4 weeks after the end of the trial

Ki nem vehet részt

  • Concomitant severe mitral or tricuspid valve disease (moderate or greater mitral or tricuspid regurgitation, or prior mitral or tricuspid valve repair/valvuloplasty/replacement)
  • Concomitant moderate or greater aortic regurgitation
  • Use, within 1 month prior to the screening visit, of medications affecting the NO-sGC-cGMP pathway (e.g., sildenafil, nitrates, etc.), or known hypersensitivity to vericiguat or its components
  • Systolic blood pressure (SBP) < 120 mmHg, or a history of symptomatic hypotension, or a history of hemodynamic instability or hypovolemia within the 4 weeks prior to screening
  • Concomitant acute myocarditis, cardiac amyloidosis, cardiac sarcoidosis, or stress (takotsubo) cardiomyopathy
  • Presence of acute coronary syndrome (including unstable angina, non-ST-segment elevation myocardial infarction, and ST-segment elevation myocardial infarction) within 60 days prior to randomization, or an indication for coronary revascularization (percutaneous intervention/bypass surgery); or a need for coronary revascularization identified at the time of randomization
  • History of cerebrovascular accident (including TIA or stroke) within 60 days prior to randomization
  • Presence of a malignancy (except those with an expected cure) or other serious non-cardiac disease with a life expectancy of less than 3 years
  • Rheumatic valvular heart disease
  • Infective endocarditis or complex congenital heart disease
  • Severe pulmonary disease requiring continuous home oxygen therapy
  • Interstitial lung disease
  • Inability to undergo contrast-enhanced CT, or contrast media allergy
  • Psychiatric disorder or legal incapacity precluding the ability to provide informed consent
  • Any medical condition, circumstance, or history that, in the investigator's judgment, would compromise the participant's ability to participate in or complete the study
  • Left ventricular ejection fraction (LVEF) < 50%, or NYHA class III-IV (see Appendix 4 for NYHA classification criteria)
  • Concomitant disorder of calcium-phosphate metabolism
  • ALT and AST ≥ 3 times the upper limit of normal, or severe hepatic insufficiency (e.g., cirrhosis, chronic active liver disease)
  • Severe aortic stenosis (AS peak velocity ≥ 4.0 m/s, or mean transvalvular aortic pressure gradient ≥ 40 mmHg, or aortic valve area ≤ 1.0 cm², or indexed effective aortic valve area < 0.6 cm²/m²), or very mild stenosis (AS peak velocity < 2.5 m/s), or a planned aortic valvuloplasty/replacement procedure
  • Presence of hypertrophic obstructive cardiomyopathy (outflow tract obstruction defined as a peak left ventricular outflow tract pressure gradient ≥ 30 mmHg at rest or after provocative testing)
  • Estimated glomerular filtration rate < 15 mL/min/1.73 m², or on dialysis
  • Current use of warfarin

A fő feltételek kérdésként

Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.

  • 35 és 80 év között vagy?

Ez a vizsgálat jelenleg itt érhető el: Kína.

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

Calcific aortic valve stenosis (CAVS) is a condition in which the aortic valve progressively narrows and stiffens due to calcium deposition, eventually impairing blood flow from the heart to the body. No drug therapy has been proven to slow CAVS progression. Individuals with mild-to-moderate CAVS are managed with periodic monitoring until the stenosis becomes severe, at which point surgical or transcatheter valve replacement is the only treatment option. The goal of this clinical trial is to determine whether vericiguat, an oral soluble guanylate cyclase (sGC) stimulator, can slow the progression of mild-to-moderate CAVS.

A teljes eredeti leírásKevesebb

The primary questions this study aims to answer are:

Does vericiguat slow the progression of aortic valve calcium accumulation, as measured by the change in aortic valve calcium score from baseline to 24 months, compared to placebo?

The study will compare vericiguat against a placebo (an inactive pill that is identical in appearance but contains no active drug). Both participants and the research team will not know which treatment each participant is receiving throughout the study.

Participants will:

Take vericiguat or placebo orally once daily for 24 months; Begin treatment at 2.5 mg/day and undergo a stepwise dose increase every two weeks to a target dose of 10 mg/day, provided the drug is tolerated; Attend approximately 8 scheduled study visits over two years, during which they will undergo cardiac imaging examinations (transthoracic echocardiography and non-contrast cardiac CT), blood sample collection, physical assessment, and completion of standardized questionnaires on quality of life and heart failure symptoms; Undergo cardiac magnetic resonance imaging (MRI) at the beginning and end of the study, if there are no contraindications.

Approximately 238 participants will be enrolled across roughly 19 hospitals in China.

A vizsgálat 2 csoportja

  • VericiguatMár használt kezelés, összehasonlításként

    Vericiguat orally once daily.

    Kezelés: Vericiguat (BAY1021189)

  • PlaceboPlacebo, összehasonlításként

    Matching placebo tablets orally once daily

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Vericiguat for the Inhibition of Calcific Aortic Valve Stenosis Progression: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial (VERIFICATION Study)
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
Kérdések a feltételekről
Forrás: NCT07715279: ki vehet részt
A regiszteradat frissítve
2026. szeptember 25.